Salbutamol

Salbutamol / Albuterol Inhalation (100mcg MDI, 200mcg Rotacaps) is the quintessential short-acting selective beta-2 adrenergic receptor agonist (SABA) on the WHO Model List of Essential Medicines. It binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase, elevating cyclic AMP, and causing rapid relaxation of bronchial smooth muscle within 3 to 5 minutes, lasting 4 to 6 hours. Indicated for immediate relief of acute bronchospasm in bronchial asthma, acute exacerbations of COPD, and prevention of exercise-induced bronchoconstriction.

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.

Salbutamol / Albuterol Inhalation (100mcg MDI, 200mcg Rotacaps) is the quintessential short-acting selective beta-2 adrenergic receptor agonist (SABA) on the WHO Model List of Essential Medicines. It binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase, elevating cyclic AMP, and causing rapid relaxation of bronchial smooth muscle within 3 to 5 minutes, lasting 4 to 6 hours. Indicated for immediate relief of acute bronchospasm in bronchial asthma, acute exacerbations of COPD, and prevention of exercise-induced bronchoconstriction.